Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00620230 | Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects | PHASE1 | COMPLETED | 46 | — | — | Oct 1, 2007 | Apr 1, 2008 | Sep 27, 2010 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NVP-VAK694 | DRUG | - |
Inclusion Criteria: * History of allergic rhinitis (Part 2 only) Exclusion Criteria: * Very low or high body weight * Heavy or recent smoker * Exposure to human monoclonal antibodies Other protocol-defined inclusion/exclusion criteria may apply.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150, Standard therapy for INCS |
| Polyrizon Ltd. | PLRZ | 1 | NA | Undisclosed |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | — | Undisclosed |